We O +
report O +
here O +
on O +
a O +
patient O +
who O +
was O +
treated O +
for O +
an O +
atypical O +
brain O +
meningioma B-Disease +
with O +
multiple O +
surgeries O +
and O +
multiple O +
sessions O +
of O +
stereotactic O +
radiosurgery O +
with O +
good O +
control O +
of O +
his O +
brain B-Disease +
disease I-Disease -
. O +

Thirteen O +
years O +
after O +
diagnosis O -
, O +
he O +
developed O +
bilateral O +
large O +
sacroiliac O +
and O +
abdominal O +
metastases O -
. O +

Extracranial O +
metastases O +
from O +
brain O +
meningiomas B-Disease +
is O +
a O +
rare O -
, O +
but O +
well O -
- O -
documented O +
entity O -
. O +

Metastases O +
occur O +
mostly O +
in O +
the O +
lungs O -
, O +
pleura O +
and O +
liver O -
, O +
but O +
may O +
also O +
affect O +
lymph O +
nodes O +
and O +
bones O -
. O +

Extraneural O +
metastases O +
from O +
cranial B-Disease +
meningioma I-Disease -
: O +
a O +
case O +
report O -
. O +

Here O +
we O +
expand O +
the O +
role O +
of O +
GRN O +
in O +
FTLD B-Disease -
- I-Disease -
U I-Disease +
and O +
demonstrate O +
that O +
a O +
common O +
genetic O +
variant O +
( O -
rs5848 O -
) O -
, O +
located O +
in O +
the O +
3'-untranslated O +
region O +
( O -
UTR O -
) O +
of O +
GRN O +
in O +
a O +
binding O -
- O -
site O +
for O +
miR-659 O -
, O +
is O +
a O +
major O +
susceptibility O +
factor O +
for O +
FTLD B-Disease -
- I-Disease -
U. I-Disease +

Loss O -
- O -
of O -
- O -
function O +
mutations O +
in O +
progranulin O +
( O -
GRN O -
) O +
cause O +
ubiquitin- O +
and O +
TAR O +
DNA O -
- O -
binding O +
protein O +
43 O +
( O -
TDP-43 O -
) O -
-positive O +
frontotemporal B-Disease +
dementia I-Disease +
( O -
FTLD B-Disease -
- I-Disease -
U I-Disease -
) O -
, O +
a O +
progressive B-Disease +
neurodegenerative I-Disease +
disease I-Disease +
affecting O +
approximately O +
10 O -
% O +
of O +
early B-Disease -
- I-Disease -
onset I-Disease +
dementia I-Disease +
patients O -
. O +

Common O +
variation O +
in O +
the O +
miR-659 O +
binding O -
- O -
site O +
of O +
GRN O +
is O +
a O +
major O +
risk O +
factor O +
for O +
TDP43-positive O +
frontotemporal B-Disease +
dementia I-Disease -
. O +

In O +
support O +
of O +
these O +
findings O -
, O +
the O +
neuropathology O +
of O +
homozygous O +
rs5848 O +
T O -
- O -
allele O +
carriers O +
frequently O +
resembled O +
the O +
pathological O +
FTLD B-Disease -
- I-Disease -
U I-Disease +
subtype O +
of O +
GRN O +
mutation O +
carriers O -
. O +

A O +
significant O +
reduction O +
in O +
GRN O +
protein O +
was O +
observed O +
in O +
homozygous O +
T O -
- O -
allele O +
carriers O +
in O +
vivo O -
, O +
through O +
biochemical O +
and O +
immunohistochemical O +
methods O -
, O +
mimicking O +
the O +
effect O +
of O +
heterozygous O +
loss O -
- O -
of O -
- O -
function O +
GRN O +
mutations O -
. O +

We O +
further O +
demonstrate O +
that O +
miR-659 O +
can O +
regulate O +
GRN O +
expression O +
in O +
vitro O -
, O +
with O +
miR-659 O +
binding O +
more O +
efficiently O +
to O +
the O +
high O +
risk O +
T O -
- O -
allele O +
of O +
rs5848 O +
resulting O +
in O +
augmented O +
translational O +
inhibition O +
of O +
GRN O -
. O +

In O +
a O +
series O +
of O +
pathologically O +
confirmed O +
FTLD B-Disease -
- I-Disease -
U I-Disease +
patients O +
without O +
GRN O +
mutations O -
, O +
we O +
show O +
that O +
carriers O +
homozygous O +
for O +
the O +
T O -
- O -
allele O +
of O +
rs5848 O +
have O +
a O +
3.2-fold O +
increased O +
risk O +
to O +
develop O +
FTLD B-Disease -
- I-Disease -
U I-Disease +
compared O +
with O +
homozygous O +
C O -
- O -
allele O +
carriers O +
( O -
95 O -
% O +
CI O -
: O +
1.50 O -
- O -
6.73 O -
) O -
. O +

Translational O +
regulation O +
by O +
miRNAs O +
may O +
represent O +
a O +
common O +
mechanism O +
underlying O +
complex O +
neurodegenerative B-Disease +
disorders I-Disease -
. O +

We O +
suggest O +
that O +
the O +
expression O +
of O +
GRN O +
is O +
regulated O +
by O +
miRNAs O +
and O +
that O +
common O +
genetic O +
variability O +
in O +
a O +
miRNA O +
binding O -
- O -
site O +
can O +
significantly O +
increase O +
the O +
risk O +
for O +
FTLD B-Disease -
- I-Disease -
U. I-Disease +

Here O -
, O +
we O +
discuss O +
recent O +
data O +
that O +
support O +
a O +
view O +
that O +
endolysosomal O +
positioning O +
of O +
RNA O +
might O +
facilitate O +
intercellular O +
transmission O +
of O +
RNA O +
and O +
host O +
defence O +
against O +
viruses O +
and O +
retrotransposons O -
. O +

Positioning O +
of O +
RNA O +
regulatory O +
mechanisms O +
on O +
endolysosomal O +
membranes O +
might O +
permit O +
rapid O +
and O +
localized O +
control O +
of O +
microRNA O +
( O -
miRNA O -
) O +
gene O +
regulatory O +
programs O +
and O +
mRNA O +
translation O +
in O +
response O +
to O +
environmental O +
signals O -
, O +
such O +
as O +
activated O +
plasma O +
membrane O +
receptors O +
transported O +
on O +
endosomes O -
. O +

Finally O -
, O +
we O +
suggest O +
that O +
the O +
pathology O +
of O +
several O +
conditions O -
, O +
including O +
Huntington B-Disease -
's I-Disease +
disease I-Disease -
, O +
might O +
be O +
a O +
consequence O +
of O +
the O +
disruption O +
of O +
the O +
control O +
of O +
RNA O +
via O +
endolysosomal O +
membranes O -
. O +

Control O +
of O +
RNA O +
silencing O +
and O +
localization O +
by O +
endolysosomes O -
. O +

Recent O +
advances O +
in O +
the O +
cell O +
biology O +
of O +
RNA O +
silencing O +
have O +
unraveled O +
an O +
intriguing O +
association O +
of O +
post O -
- O -
transcriptionally O +
regulated O +
RNA O +
with O +
endolysosomal O +
membranes O +
in O +
several O +
circumstances O +
of O +
mRNA O +
localization O -
, O +
microRNA O +
activity O +
and O +
viral O +
RNA O +
transport O +
and O +
packaging O -
. O +

Endolysosomal O +
membranes O +
are O +
a O +
nexus O +
of O +
communication O +
and O +
transport O +
between O +
cells O +
and O +
their O +
exterior O +
environment O +
for O +
signaling O +
receptors O -
, O +
pathogens O +
and O +
nutrients O -
. O +

The O +
method O +
by O +
which O +
MSCs O +
could O +
be O +
applied O +
for O +
future O +
therapies O +
might O +
require O +
trans O -
- O -
disciplinary O +
approaches O +
for O +
personalized O +
treatments O -
. O +

Implantation O +
of O +
adult O +
human O +
mesenchymal O +
stem O +
cells O +
( O -
MSCs O -
) O +
to O +
treat O +
neural B-Disease +
disorders I-Disease +
shows O +
promise O -
. O +

Depending O +
on O +
their O +
microenvironment O -
, O +
MSCs O +
could O +
potentially O +
be O +
used O +
for O +
the O +
repair O +
and/or O +
replacement O +
of O +
neurons O +
in O +
traumatic O +
brain B-Disease +
injury I-Disease +
or O +
the O +
treatment O +
of O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
. O +

This O +
cross O -
- O -
disciplinary O +
review O +
incorporates O +
aspects O +
of O +
neuroscience O -
, O +
stem O +
cell O +
biology O -
, O +
cancer B-Disease +
biology O +
and O +
immunology O +
to O +
discuss O +
interactions O +
between O +
inflammatory O +
mediators O +
and O +
MSCs O -
. O +

We O +
first O +
discuss O +
the O +
role O +
of O +
microRNAs O +
( O -
miRNAs O -
) O +
in O +
neurological O +
development O -
. O +

Neurogenesis O -
: O +
role O +
for O +
microRNAs O +
and O +
mesenchymal O +
stem O +
cells O +
in O +
pathological O +
states O -
. O +

Exploring O +
the O +
predisposition O +
of O +
MSCs O +
to O +
oncogenesis O +
is O +
critical O +
for O +
translational O +
science O +
since O +
the O +
implementation O +
of O +
safeguarding O +
measures O +
prior O +
to O +
therapy O +
can O +
lead O +
to O +
the O +
successful O +
delivery O +
of O +
stem O +
cells O +
to O +
patients O -
. O +

The O +
administration O +
of O +
effective O +
and O +
safe O +
MSC O +
therapy O +
must O +
acknowledge O +
immune O +
mediators O +
that O +
may O +
predispose O +
the O +
early O +
differentiating O +
MSCs O +
to O +
oncogenic O +
insults O -
. O +

Secondly O -
, O +
we O +
discuss O +
the O +
ability O +
of O +
MSCs O +
to O +
transdifferentiate O +
into O +
functional O +
neurons O -
, O +
which O +
are O +
regulated O +
by O +
miRNAs O -
, O +
and O +
the O +
implications O +
of O +
these O +
cells O +
for O +
the O +
therapy O +
of O +
neuropathological O +
states O -
. O +

Immune O +
mediators O +
could O +
be O +
central O +
to O +
MSC O +
responses O +
within O +
a O +
region O +
of O +
tissue B-Disease +
injury I-Disease +
and O +
are O +
also O +
discussed O +
in O +
detail O -
. O +

Thus O -
, O +
we O +
discuss O +
a O +
key O +
gene O -
, O +
RE-1 O +
silencing O +
transcription O +
factor O +
( O -
REST O -
) O -
, O +
based O +
on O +
its O +
dual O +
role O +
in O +
neurogenesis O +
and O +
cancer B-Disease +
development O -
. O +

Finally O -
, O +
a O +
phylogenetic O +
analysis O +
shows O +
that O +
ADCK3 O +
belongs O +
to O +
the O +
family O +
of O +
atypical O +
kinases O -
, O +
which O +
includes O +
phosphoinositide O +
and O +
choline O +
kinases O -
, O +
suggesting O +
that O +
ADCK3 O +
plays O +
an O +
indirect O +
regulatory O +
role O +
in O +
ubiquinone O +
biosynthesis O +
possibly O +
as O +
part O +
of O +
a O +
feedback O +
loop O +
that O +
regulates O +
ATP O +
production O -
. O +

ADCK3 O -
, O +
an O +
ancestral O +
kinase O -
, O +
is O +
mutated O +
in O +
a O +
form O +
of O +
recessive B-Disease +
ataxia I-Disease +
associated O +
with O +
coenzyme O +
Q10 O +
deficiency O -
. O +

Muscle O +
coenzyme O +
Q O -
( O -
10 O -
) O +
( O -
CoQ O -
( O -
10 O -
) O +
or O +
ubiquinone O -
) O +
deficiency O +
has O +
been O +
identified O +
in O +
more O +
than O +
20 O +
patients O +
with O +
presumed O +
autosomal B-Disease -
- I-Disease -
recessive I-Disease +
ataxia I-Disease -
. O +

However O -
, O +
mutations O +
in O +
genes O +
required O +
for O +
CoQ O -
( O -
10 O -
) O +
biosynthetic O +
pathway O +
have O +
been O +
identified O +
only O +
in O +
patients O +
with O +
infantile O -
- O -
onset O +
multisystemic O +
diseases O +
or O +
isolated B-Disease +
nephropathy I-Disease -
. O +

Our O +
SNP O -
- O -
based O +
genome O -
- O -
wide O +
scan O +
in O +
a O +
large O +
consanguineous O +
family O +
revealed O +
a O +
locus O +
for O +
autosomal B-Disease -
- I-Disease -
recessive I-Disease +
ataxia I-Disease +
at O +
chromosome O +
1q41 O -
. O +

The O +
causative O +
mutation O +
is O +
a O +
homozygous O +
splice O -
- O -
site O +
mutation O +
in O +
the O +
aarF O -
- O -
domain O -
- O -
containing O +
kinase O +
3 O +
gene O +
( O -
ADCK3 O -
) O -
. O +

Five O +
additional O +
mutations O +
in O +
ADCK3 O +
were O +
found O +
in O +
three O +
patients O +
with O +
sporadic B-Disease +
ataxia I-Disease -
, O +
including O +
one O +
known O +
to O +
have O +
CoQ O -
( O -
10 O -
) O +
deficiency O +
in O +
muscle O -
. O +

All O +
of O +
the O +
patients O +
have O +
childhood O -
- O -
onset O +
cerebellar B-Disease +
ataxia I-Disease +
with O +
slow O +
progression O -
, O +
and O +
three O +
of O +
six O +
have O +
mildly O +
elevated O +
lactate O +
levels O -
. O +

ADCK3 O +
is O +
a O +
mitochondrial O +
protein O +
homologous O +
to O +
the O +
yeast O +
COQ8 O +
and O +
the O +
bacterial O +
UbiB O +
proteins O -
, O +
which O +
are O +
required O +
for O +
CoQ O +
biosynthesis O -
. O +

Three O +
out O +
of O +
four O +
patients O +
tested O +
showed O +
a O +
low O +
endogenous O +
pool O +
of O +
CoQ O -
( O -
10 O -
) O +
in O +
their O +
fibroblasts O +
or O +
lymphoblasts O -
, O +
and O +
two O +
out O +
of O +
three O +
patients O +
showed O +
impaired O +
ubiquinone O +
synthesis O -
, O +
strongly O +
suggesting O +
that O +
ADCK3 O +
is O +
also O +
involved O +
in O +
CoQ O -
( O -
10 O -
) O +
biosynthesis O -
. O +

The O +
deleterious O +
nature O +
of O +
the O +
three O +
identified O +
missense O +
changes O +
was O +
confirmed O +
by O +
the O +
introduction O +
of O +
them O +
at O +
the O +
corresponding O +
positions O +
of O +
the O +
yeast O +
COQ8 O +
gene O -
. O +

Interpretation O +
and O +
applicability O +
of O +
microRNA O +
data O +
to O +
the O +
context O +
of O +
Alzheimer B-Disease -
's I-Disease +
and O +
age O -
- O -
related O +
diseases O -
. O +

Generated O +
by O +
the O +
ribonuclease O +
III O +
Dicer O -
, O +
microRNAs O +
( O -
miRNAs O -
) O +
are O +
predicted O +
to O +
regulate O +
up O +
to O +
90 O -
% O +
of O +
the O +
genes O +
in O +
humans O -
, O +
suggesting O +
that O +
they O +
may O +
control O +
every O +
cellular O +
processes O +
in O +
all O +
cells O +
and O +
tissues O +
of O +
the O +
human O +
body O -
! O +

Likely O +
to O +
play O +
a O +
central O +
role O +
in O +
health O +
and O +
disease O -
, O +
a O +
dysfunctional O +
miRNA O -
- O -
based O +
regulation O +
of O +
gene O +
expression O +
may O +
represent O +
the O +
main O +
etiologic O +
factor O +
underlying O +
age O -
- O -
related O +
diseases O +
affecting O +
major O +
organs O -
, O +
such O +
as O +
the O +
brain O -
. O +

Here O -
, O +
we O +
discuss O +
some O +
of O +
the O +
limitations O +
associated O +
to O +
the O +
interpretation O +
and O +
applicability O +
of O +
miRNA O +
data O -
, O +
based O +
on O +
our O +
recent O +
study O +
on O +
the O +
etiology O +
of O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease +
( O -
AD B-Disease -
) O -
. O +

Using O +
transiently O +
transfected O +
murine O +
neuronal O +
N2a O +
cells O +
in O +
culture O -
, O +
in O +
parallel O +
to O +
a O +
mouse O +
model O +
of O +
AD B-Disease -
, O +
we O +
were O +
able O +
to O +
demonstrate O +
a O +
role O +
for O +
two O +
miRNAs O +
( O -
miR-298 O +
and O +
miR-328 O -
) O +
in O +
the O +
regulation O +
of O +
beta O -
- O -
amyloid O +
( O -
Abeta O -
) O +
precursor O +
protein O +
( O -
APP O -
) O -
-converting O +
enzyme O +
( O -
BACE O -
) O +
messenger O +
RNA O +
( O -
mRNA O -
) O +
translation O -
, O +
thereby O +
providing O +
key O +
insights O +
into O +
the O +
molecular O +
basis O +
underlying O +
BACE O +
deregulation O +
in O +
AD B-Disease -
. O +

However O -
, O +
whether O +
miRNA O +
data O +
can O +
be O +
extrapolated O +
and O +
transposed O +
to O +
the O +
human O +
context O +
of O +
age O -
- O -
related O +
diseases O -
, O +
such O +
as O +
AD B-Disease -
, O +
not O +
only O +
requires O +
caution O -
, O +
but O +
also O +
warrants O +
several O +
considerations O -
. O +

Levels O +
of O +
protein O +
expression O +
of O +
endothelial O +
NO O +
synthase O +
( O -
eNOS O -
) O -
, O +
caveolin-1 O -
, O +
and O +
calmodulin O +
were O +
assessed O +
in O +
carotid O +
arteries O +
using O +
Western O +
analysis O -
. O +

Plasma O +
NO O +
levels O +
were O +
doubled O +
by O +
daidzein O +
or O +
17beta O -
- O -
estradiol O -
. O +

NO O +
production O +
and O +
endothelium O -
- O -
dependent O +
contraction O +
in O +
response O +
to O +
the O +
NOS O +
inhibitor O +
NG O -
- O -
nitro O -
- O -
L O -
- O -
arginine O +
( O -
L O -
- O -
NNA O -
; O +
100 O +
microM O -
) O +
was O +
enhanced O +
by O +
50 O +
to O +
100 O -
% O +
in O +
carotid O +
arteries O +
from O +
rats O +
treated O +
with O +
daidzein O +
or O +
17beta O -
- O -
estradiol O -
. O +

Acetylcholine O -
- O -
induced O +
relaxation O +
was O +
selectively O +
enhanced O +
in O +
carotid O +
arteries O +
from O +
rats O +
treated O +
with O +
daidzein O -
. O +

The O +
use O +
of O +
estrogen O +
for O +
protection O +
against O +
vascular B-Disease +
dysfunction I-Disease +
is O +
limited O +
due O +
to O +
its O +
effects O +
on O +
the O +
reproductive O +
system O -
, O +
particularly O +
in O +
males O -
. O +

We O +
postulated O +
that O +
daidzein O -
, O +
an O +
isoflavone O +
with O +
estrogen O -
- O -
like O +
effects O +
on O +
the O +
systemic O +
vasculature O +
but O +
not O +
the O +
reproductive O +
system O -
, O +
might O +
enhance O +
nitric O +
oxide O +
( O -
NO O -
) O -
-mediated O +
cerebral O +
vasodilatation O -
. O +

Male O +
rats O +
were O +
administered O +
vehicle O -
, O +
17beta O -
- O -
estradiol O +
( O -
0.1 O +
mg O -
/ O -
kg O +
s.c O -
. O -
) O -
, O +
or O +
daidzein O +
( O -
0.2 O +
mg O -
/ O -
kg O +
s.c O -
. O -
) O +
daily O +
for O +
7 O +
days O -
. O +

Basal O +
and O +
acetylcholine O -
- O -
stimulated O +
NO O +
release O +
was O +
assessed O +
in O +
vitro O +
via O +
carotid O +
arterial O +
rings O +
or O +
in O +
vivo O +
by O +
measuring O +
changes O +
in O +
basilar O +
artery O +
diameter O -
. O +

Similarly O -
, O +
constrictor O +
responses O +
of O +
the O +
basilar O +
artery O +
to O +
L O -
- O -
NNA O +
in O +
vivo O +
were O +
selectively O +
augmented O +
by O +
approximately O +
100 O -
% O +
by O +
17beta O -
- O -
estradiol O +
treatment O +
and O +
tended O +
to O +
be O +
approximately O +
50 O -
% O +
greater O +
in O +
daidzein O -
- O -
treated O +
rats O -
. O +

Effect O +
of O +
short O -
- O -
term O +
phytoestrogen O +
treatment O +
in O +
male O +
rats O +
on O +
nitric O +
oxide O -
- O -
mediated O +
responses O +
of O +
carotid O +
and O +
cerebral O +
arteries O -
: O +
comparison O +
with O +
17beta O -
- O -
estradiol O -
. O +

These O +
data O +
suggest O +
that O +
short O -
- O -
term O +
administration O +
of O +
daidzein O +
or O +
17beta O -
- O -
estradiol O +
modulates O +
cerebral O +
artery O +
reactivity O +
in O +
males O +
by O +
enhancing O +
synthesis O +
and O +
release O +
of O +
endothelium O -
- O -
derived O +
NO O -
. O +
Isoflavone O +
therapy O +
may O +
therefore O +
be O +
a O +
feasible O +
approach O +
to O +
protect O +
against O +
cerebrovascular B-Disease +
disease I-Disease +
and O +
stroke B-Disease -
. O +

Expression O +
of O +
caveolin-1 O +
was O +
decreased O -
, O +
and O +
calmodulin O +
was O +
increased O -
, O +
in O +
vessels O +
from O +
daidzein- O +
or O +
17beta O -
- O -
estradiol O -
- O -
treated O +
rats O -
. O +

eNOS O +
expression O +
was O +
unaffected O +
by O +
the O +
treatments O -
. O +

However O -
, O +
we O +
report O +
the O +
experience O +
of O +
a O +
patient O +
who O +
inadvertently O +
received O +
live O +
polio B-Disease +
vaccine O +
whilst O +
receiving O +
anti O -
- O -
TNF O +
therapy O -
. O +

International O +
guidelines O +
state O +
that O +
live O +
vaccines O +
are O +
contraindicated O +
in O +
patients O +
on O +
anti O -
- O -
TNF O +
therapy O -
. O +

Live O +
polio B-Disease +
vaccine O +
exposure O +
while O +
receiving O +
anti O -
- O -
TNF O +
therapy O +
for O +
reactive O +
arthritis B-Disease -
. O +

Patients O +
should O +
be O +
counseled O +
regarding O +
the O +
risks O +
of O +
live O +
vaccines O +
prior O +
to O +
treatment O +
with O +
anti O -
- O -
TNF O +
therapy O -
. O +

However O -
, O +
if O +
we O +
consider O +
adult O +
patients O +
with O +
rheumatic B-Disease +
diseases I-Disease +
to O +
have O +
altered O +
immunocompetence O -
, O +
it O +
is O +
recommended O +
that O +
they O +
receive O +
the O +
usual O +
inactivated O +
vaccines O +
according O +
to O +
standard O +
schedules O -
, O +
and O +
live O +
vaccines O +
should O +
be O +
avoided O +
in O +
those O +
who O +
are O +
treated O +
with O +
more O +
potent O +
forms O +
of O +
immune O +
suppression O -
. O +

No O +
clear O +
guidelines O +
are O +
available O +
for O +
all O +
vaccines O +
in O +
patients O +
with O +
specific O +
rheumatic B-Disease +
diseases I-Disease -
. O +

Patient O +
did O +
not O +
suffer O +
from O +
any O +
infectious O +
sequel O +
as O +
a O +
result O -
. O +

Autosomal B-Disease -
- I-Disease -
recessive I-Disease +
cerebellar I-Disease +
ataxias I-Disease +
comprise O +
a O +
clinically O +
and O +
genetically O +
heterogeneous O +
group O +
of O +
neurodegenerative B-Disease +
disorders I-Disease -
. O +

In O +
contrast O +
to O +
their O +
dominant O +
counterparts O -
, O +
unraveling O +
the O +
molecular O +
background O +
of O +
these O +
ataxias B-Disease +
has O +
proven O +
to O +
be O +
more O +
complicated O +
and O +
the O +
currently O +
known O +
mutations O +
provide O +
incomplete O +
coverage O +
for O +
genotyping O +
of O +
patients O -
. O +

By O +
combining O +
SNP O +
array O -
- O -
based O +
linkage O +
analysis O +
and O +
targeted O +
resequencing O +
of O +
relevant O +
sequences O +
in O +
the O +
linkage O +
interval O +
with O +
the O +
use O +
of O +
next O -
- O -
generation O +
sequencing O +
technology O -
, O +
we O +
identified O +
a O +
mutation O +
in O +
a O +
gene O +
and O +
have O +
shown O +
its O +
association O +
with O +
autosomal B-Disease -
- I-Disease -
recessive I-Disease +
cerebellar I-Disease +
ataxia I-Disease -
. O +

In O +
a O +
Dutch O +
consanguineous O +
family O +
with O +
three O +
affected O +
siblings O +
a O +
homozygous O +
12.5 O +
Mb O +
region O +
on O +
chromosome O +
3 O +
was O +
targeted O +
by O +
array O -
- O -
based O +
sequence O +
capture O -
. O +

Targeted O +
next O -
- O -
generation O +
sequencing O +
of O +
a O +
12.5 O +
Mb O +
homozygous O +
region O +
reveals O +
ANO10 O +
mutations O +
in O +
patients O +
with O +
autosomal B-Disease -
- I-Disease -
recessive I-Disease +
cerebellar I-Disease +
ataxia I-Disease -
. O +

The O +
analysis O +
of O +
ANO10 O +
by O +
Sanger O +
sequencing O +
revealed O +
three O +
additional O +
mutations O -
: O +
a O +
homozygous O +
mutation O +
( O -
c.1150_1151del O +
[ O -
p O -
. O -
Leu384fs O -
] O -
) O +
in O +
a O +
Serbian O +
family O +
and O +
a O +
compound O -
- O -
heterozygous O +
splice O -
- O -
site O +
mutation O +
( O -
c.1476 O -
+ O -
1G O -
> O -
T O -
) O +
and O +
a O +
frameshift O +
mutation O +
( O -
c.1604del O +
[ O -
p O -
. O -
Leu535X O -
] O -
) O +
in O +
a O +
French O +
family O -
. O +

This O +
illustrates O +
the O +
power O +
of O +
using O +
initial O +
homozygosity O +
mapping O +
with O +
next O -
- O -
generation O +
sequencing O +
technology O +
to O +
identify O +
genes O +
involved O +
in O +
autosomal O -
- O -
recessive O +
diseases O -
. O +

Prioritization O +
of O +
all O +
detected O +
sequence O +
variants O +
led O +
to O +
four O +
candidate O +
genes O -
, O +
one O +
of O +
which O +
contained O +
a O +
variant O +
with O +
a O +
high O +
base O +
pair O +
conservation O +
score O +
( O -
phyloP O +
score O -
: O +
5.26 O -
) O -
. O +

This O +
variant O +
was O +
a O +
leucine O -
- O -
to O -
- O -
arginine O +
substitution O +
in O +
the O +
DUF O +
590 O +
domain O +
of O +
a O +
16 O -
K O +
transmembrane O +
protein O -
, O +
a O +
putative O +
calcium O -
- O -
activated O +
chloride O +
channel O +
encoded O +
by O +
anoctamin O +
10 O +
( O -
ANO10 O -
) O -
. O +

Moreover O -
, O +
identifying O +
a O +
putative O +
calcium O -
- O -
dependent O +
chloride O +
channel O +
involved O +
in O +
cerebellar B-Disease +
ataxia I-Disease +
adds O +
another O +
pathway O +
to O +
the O +
list O +
of O +
pathophysiological O +
mechanisms O +
that O +
may O +
cause O +
cerebellar B-Disease +
ataxia I-Disease -
. O +

These O +
findings O +
further O +
support O +
the O +
idea O +
that O +
iron- O +
and O +
aluminum O -
- O -
sulfates O +
induce O +
genotoxicity O +
via O +
a O +
ROS O -
- O -
mediated O +
up O -
- O -
regulation O +
of O +
specific O +
regulatory O +
elements O +
and O +
pathogenic O +
genes O +
that O +
redirect O +
brain O +
cell O +
fate O +
towards O +
progressive O +
dysfunction O +
and O +
apoptotic O +
cell O +
death O -
. O +

Notably O -
, O +
these O +
same O +
miRNAs O +
are O +
up O -
- O -
regulated O +
in O +
AD B-Disease +
brain O -
. O +

The O +
main O +
finding O +
was O +
that O +
these O +
ROS O -
- O -
generating O +
neurotoxic O +
metal O +
sulfates O +
also O +
up O -
- O -
regulate O +
a O +
specific O +
set O +
of O +
miRNAs O +
that O +
includes O +
miR-9 O -
, O +
miR-125b O +
and O +
miR-128 O -
. O +

In O +
this O +
study O +
we O +
have O +
extended O +
our O +
investigations O +
to O +
analyze O +
the O +
expression O +
of O +
micro O +
RNA O +
( O -
miRNA O -
) O +
populations O +
in O +
iron- O +
and O +
aluminum O -
- O -
sulfate O +
treated O +
human O +
neural O +
cells O +
in O +
primary O +
culture O -
. O +

Notably O -
, O +
iron- O +
and O +
aluminum O -
- O -
sulfate O +
induce O +
genes O +
in O +
cultured O +
human O +
brain O +
cells O +
that O +
exhibit O +
expression O +
patterns O +
similar O +
to O +
those O +
observed O +
to O +
be O +
up O -
- O -
regulated O +
in O +
moderate- O +
to O +
late O -
- O -
stage O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease +
( O -
AD B-Disease -
) O -
. O +

Previous O +
studies O +
have O +
shown O +
that O +
following O +
ROS O +
induction O -
, O +
a O +
family O +
of O +
pathogenic O +
brain O +
genes O +
that O +
promote O +
inflammatory O +
signalling O -
, O +
cellular O +
apoptosis O +
and O +
brain O +
cell O +
death O +
is O +
significantly O +
over O -
- O -
expressed O -
. O +

Iron- O +
and O +
aluminum O -
- O -
sulfate O +
together O -
, O +
at O +
nanomolar O +
concentrations O -
, O +
trigger O +
the O +
production O +
of O +
reactive O +
oxygen O +
species O +
( O -
ROS O -
) O +
in O +
cultures O +
of O +
human O +
brain O +
cells O -
. O +

Induction O +
of O +
specific O +
micro O +
RNA O +
( O -
miRNA O -
) O +
species O +
by O +
ROS O -
- O -
generating O +
metal O +
sulfates O +
in O +
primary O +
human O +
brain O +
cells O -
. O +

The O +
rapid O +
and O +
exciting O +
pace O +
of O +
advances O +
in O +
glioblastoma B-Disease +
genetics O +
has O +
prompted O +
this O +
up O -
- O -
to O -
- O -
date O +
review O -
. O +

The O +
likely O +
impact O +
on O +
care O +
delivery O +
in O +
the O +
clinic O +
may O +
only O +
be O +
a O +
few O +
years O +
away O -
. O +

Within O +
the O +
last O +
few O +
years O -
, O +
high O -
- O -
throughput O +
efforts O +
such O +
as O +
The O +
Cancer O +
Genome O +
Atlas O +
and O +
a O +
massive O +
sequencing O +
project O +
have O +
yielded O +
novel O +
insights O +
and O +
classifications O +
of O +
this O +
dreaded O +
cancer B-Disease -
. O +

It O +
has O +
been O +
hoped O +
that O +
dissection O +
of O +
the O +
genetics O +
of O +
this O +
cancer B-Disease +
would O +
lead O +
to O +
more O +
targeted O +
and O +
effective O +
treatments O -
, O +
and O +
new O +
advances O +
may O +
finally O +
be O +
bringing O +
this O +
closer O +
to O +
fruition O -
. O +

Glioblastoma B-Disease +
genetics O -
: O +
in O +
rapid O +
flux O -
. O +

Glioblastoma B-Disease +
is O +
the O +
most O +
common O +
and O +
most O +
lethal O +
primary B-Disease +
brain I-Disease +
tumor I-Disease -
. O +

While O +
small O +
progress O +
has O +
been O +
made O +
in O +
treating O +
this O +
cancer B-Disease +
in O +
recent O +
years O -
, O +
glioblastoma B-Disease +
remains O +
largely O +
resistant O +
to O +
all O +
existing O +
therapies O -
. O +

Novel O +
animal O +
models O +
for O +
studying O +
complex O +
brain B-Disease +
disorders I-Disease -
: O +
BAC O -
- O -
driven O +
miRNA O -
- O -
mediated O +
in O +
vivo O +
silencing O +
of O +
gene O +
expression O -
. O +

In O +
schizophrenia B-Disease -
, O +
glutamic O +
acid O +
decarboxylase O +
1 O +
( O -
GAD1 O -
) O +
disturbances O +
are O +
robust O -
, O +
consistently O +
observed O -
, O +
cell O -
- O -
type O +
specific O +
and O +
represent O +
a O +
core O +
feature O +
of O +
the O +
disease O -
. O +

In O +
addition O -
, O +
neuropeptide O +
Y O +
( O -
NPY O -
) O -
, O +
which O +
is O +
a O +
phenotypic O +
marker O +
of O +
a O +
sub O -
- O -
population O +
of O +
GAD1-containing O +
interneurons O -
, O +
has O +
shown O +
reduced O +
expression O +
in O +
the O +
prefrontal O +
cortex O +
in O +
subjects O +
with O +
schizophrenia B-Disease -
, O +
suggesting O +
that O +
dysfunction O +
of O +
the O +
NPY+ O +
cortical O +
interneuronal O +
sub O -
- O -
population O +
might O +
be O +
a O +
core O +
feature O +
of O +
this O +
devastating O +
disorder O -
. O +

However O -
, O +
modeling O +
gene O +
expression O +
disturbances O +
in O +
schizophrenia B-Disease +
in O +
a O +
cell O +
type O -
- O -
specific O +
manner O +
has O +
been O +
extremely O +
challenging O -
. O +

To O +
more O +
closely O +
mimic O +
these O +
molecular O +
and O +
cellular O +
human O +
post O -
- O -
mortem O +
findings O -
, O +
we O +
generated O +
a O +
transgenic O +
mouse O +
in O +
which O +
we O +
downregulated O +
GAD1 O +
mRNA O +
expression O +
specifically O +
in O +
NPY+ O +
neurons O -
. O +

This O +
novel O -
, O +
cell O +
type O -
- O -
specific O +
in O +
vivo O +
system O +
for O +
reducing O +
gene O +
expression O +
uses O +
a O +
bacterial O +
artificial O +
chromosome O +
( O -
BAC O -
) O +
containing O +
the O +
NPY O +
promoter O -
- O -
enhancer O +
elements O -
, O +
the O +
reporter O +
molecule O +
( O -
eGFP O -
) O +
and O +
a O +
modified O +
intron O +
containing O +
a O +
synthetic O +
microRNA O +
( O -
miRNA O -
) O +
targeted O +
to O +
GAD1 O -
. O +

The O +
animals O +
of O +
isogenic O +
strains O +
are O +
generated O +
rapidly O -
, O +
providing O +
a O +
new O +
tool O +
for O +
better O +
understanding O +
the O +
molecular O +
disturbances O +
in O +
the O +
GABAergic O +
system O +
observed O +
in O +
complex O +
neuropsychiatric B-Disease +
disorders I-Disease +
such O +
as O +
schizophrenia B-Disease -
. O +

In O +
the O +
future O -
, O +
because O +
of O +
the O +
small O +
size O +
of O +
the O +
silencing O +
miRNAs O +
combined O +
with O +
our O +
BAC O +
strategy O -
, O +
this O +
method O +
may O +
be O +
modified O +
to O +
allow O +
generation O +
of O +
mice O +
with O +
simultaneous O +
silencing O +
of O +
multiple O +
genes O +
in O +
the O +
same O +
cells O +
with O +
a O +
single O +
construct O -
, O +
and O +
production O +
of O +
splice O -
- O -
variant O -
- O -
specific O +
knockdown O +
animals O -
. O +

Biomarkers O +
associated O +
with O +
metastasis O +
of O +
lung B-Disease +
cancer I-Disease +
to O +
brain O +
predict O +
patient O +
survival O -
. O +

This O +
research O +
involves O +
comprehensive O +
miRNA O +
expression O +
profiling O -
, O +
evaluation O +
of O +
normalisation O +
techniques O +
and O +
combination O +
of O +
miRNA O +
with O +
imaging O +
features O +
FDG O -
- O -
PET O -
/ O -
CT O +
and O +
CT O +
Scan O -
. O +

We O +
combine O +
validated O +
miRNA O +
expression O +
values O +
with O +
imaging O +
features O +
to O +
classify O +
NSCLC O +
brain O +
mets O +
from O +
non O -
- O -
brain O +
mets O +
and O +
identify O +
possible O +
biomarkers O +
of O +
brain O +
mets O -
. O +

Generally O -
, O +
one O +
miRNA O +
is O +
predicted O +
to O +
regulate O +
several O +
hundred O +
genes O -
, O +
and O +
as O +
a O +
result O -
, O +
miRNAs O +
could O +
serve O +
as O +
a O +
better O +
classifier O +
than O +
gene O +
expression O -
. O +

MicroRNAs O +
influence O +
cell O +
physiology O -
; O +
alteration O +
in O +
miRNA O +
regulation O +
can O +
be O +
implicated O +
in O +
carcinogenesis O +
and O +
disease O +
progression O -
. O +

The O +
biomarkers O +
were O +
validated O +
on O +
an O +
independent O +
data O +
set O +
to O +
predict O +
potential O +
brain O +
mets O -
. O +

Through O +
various O +
experimental O +
approaches O -
, O +
we O +
validated O +
computational O +
predictions O +
and O +
demonstrated O +
that O +
miR-298 O +
and O +
miR-328 O +
recognize O +
specific O +
binding O +
sites O +
in O +
the O +
3'-UTR O +
of O +
BACE1 O +
mRNA O +
and O +
exert O +
regulatory O +
effects O +
on O +
BACE1 O +
protein O +
expression O +
in O +
cultured O +
neuronal O +
cells O -
. O +

Here O +
we O +
also O +
observed O +
a O +
loss O +
of O +
correlation O +
between O +
BACE1 O +
mRNA O +
and O +
protein O +
levels O +
in O +
the O +
hippocampus O +
of O +
a O +
mouse O +
model O +
of O +
AD B-Disease -
. O +
Consistent O +
with O +
an O +
impairment O +
of O +
miRNA O -
- O -
mediated O +
regulation O +
of O +
BACE1 O +
expression O -
, O +
these O +
findings O +
prompted O +
us O +
to O +
investigate O +
the O +
regulatory O +
role O +
of O +
the O +
BACE1 O +
3'-UTR O +
element O +
and O +
the O +
possible O +
involvement O +
of O +
specific O +
miRNAs O +
in O +
cultured O +
neuronal O +
( O -
N2a O -
) O +
and O +
fibroblastic O +
( O -
NIH O +
3T3 O -
) O +
cells O -
. O +

Our O +
results O +
may O +
provide O +
the O +
molecular O +
basis O +
underlying O +
BACE1 O +
deregulation O +
in O +
AD B-Disease +
and O +
offer O +
new O +
perspectives O +
on O +
the O +
etiology O +
of O +
this O +
neurological B-Disease +
disorder I-Disease -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
key O +
regulatory O +
RNAs O +
known O +
to O +
repress O +
mRNA O +
translation O +
through O +
recognition O +
of O +
specific O +
binding O +
sites O +
located O +
mainly O +
in O +
their O +
3'-untranslated O +
region O +
( O -
UTR O -
) O -
. O +

MicroRNA-298 O +
and O +
microRNA-328 O +
regulate O +
expression O +
of O +
mouse O +
beta O -
- O -
amyloid O +
precursor O +
protein O -
- O -
converting O +
enzyme O +
1 O -
. O +

Intriguingly O -
, O +
previous O +
post O -
- O -
mortem O +
analyses O +
showed O +
higher O +
beta O -
- O -
amyloid O +
precursor O +
protein O -
- O -
converting O +
enzyme O +
( O -
BACE O -
) O +
protein O -
, O +
but O +
not O +
mRNA O -
, O +
levels O +
in O +
the O +
brain O +
of O +
patients O +
that O +
suffered O +
from O +
Alzheimer B-Disease +
disease I-Disease +
( O -
AD B-Disease -
) O -
. O +

Loss O +
of O +
specific O +
miRNA O +
control O +
of O +
gene O +
expression O +
is O +
thus O +
expected O +
to O +
underlie O +
serious O +
genetic O +
diseases O -
. O +

These O +
findings O +
reveal O +
a O +
significant O +
additional O +
mechanism O +
by O +
which O +
alpha O -
- O -
synuclein O +
is O +
regulated O +
and O +
point O +
toward O +
new O +
therapeutic O +
regimes O +
for O +
lowering O +
endogenous O +
alpha O -
- O -
synuclein O +
levels O +
in O +
patients O +
with O +
familial O +
or O +
sporadic B-Disease +
Parkinson I-Disease +
disease I-Disease -
. O +

Overexpression O +
of O +
mir-7 O +
and O +
mir-153 O +
significantly O +
reduces O +
endogenous O +
alpha O -
- O -
synuclein O +
levels O -
, O +
whereas O +
inhibition O +
of O +
mir-7 O +
and O +
mir-153 O +
enhances O +
translation O +
of O +
a O +
luciferase O +
construct O +
bearing O +
the O +
alpha O -
- O -
synuclein O +
3'-untranslated O +
region O +
in O +
primary O +
neurons O -
. O +

They O +
are O +
expressed O +
predominantly O +
in O +
the O +
brain O +
with O +
a O +
pattern O +
that O +
mirrors O +
synuclein O +
expression O +
in O +
different O +
tissues O +
as O +
well O +
as O +
during O +
neuronal O +
development O -
, O +
indicating O +
that O +
they O +
play O +
a O +
tuning O +
role O +
in O +
the O +
amount O +
of O +
alpha O -
- O -
synuclein O +
produced O -
. O +

These O +
microRNAs O +
bind O +
specifically O +
to O +
the O +
3'-untranslated O +
region O +
of O +
alpha O -
- O -
synuclein O +
and O +
down O -
- O -
regulate O +
its O +
mRNA O +
and O +
protein O +
levels O -
, O +
with O +
their O +
effect O +
being O +
additive O -
. O +

Here O -
, O +
two O +
microRNAs O -
, O +
namely O +
mir-7 O +
and O +
mir-153 O -
, O +
have O +
been O +
identified O +
to O +
regulate O +
alpha O -
- O -
synuclein O +
levels O +
post O -
- O -
transcriptionally O -
. O +

Genetic O +
and O +
biochemical O +
studies O +
have O +
established O +
a O +
central O +
role O +
for O +
alpha O -
- O -
synuclein O +
accumulation O +
in O +
the O +
pathogenesis O +
of O +
Parkinson B-Disease +
disease I-Disease -
. O +

Post O -
- O -
transcriptional O +
regulation O +
of O +
alpha O -
- O -
synuclein O +
expression O +
by O +
mir-7 O +
and O +
mir-153 O -
. O +

Learning O -
, O +
retention O +
and O +
generalization O +
of O +
a O +
mirror O +
tracing O +
skill O +
in O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease -
. O +

The O +
present O +
study O +
examined O +
the O +
ability O +
of O +
12 O +
patients O +
with O +
probable O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease +
( O -
AD B-Disease -
) O +
and O +
12 O +
age- O +
and O +
education O -
- O -
matched O +
normal O +
control O +
( O -
NC O -
) O +
subjects O +
to O +
learn O +
and O +
retain O +
the O +
visuomotor O +
skills O +
necessary O +
to O +
efficiently O +
trace O +
a O +
pattern O +
( O -
e.g. O -
, O +
a O +
4- O +
or O +
6-pointed O +
star O -
) O +
seen O +
only O +
in O +
mirror O -
- O -
reversed O +
view O -
. O +

Those O +
AD B-Disease +
( O -
N=6 O -
) O +
and O +
NC O +
( O -
N=7 O -
) O +
subjects O +
who O +
were O +
able O +
to O +
initially O +
perform O +
the O +
basic O +
mirror O +
tracing O +
task O +
did O +
not O +
differ O +
significantly O +
in O +
initial O +
level O +
of O +
performance O -
, O +
learning O +
over O +
trials O -
, O +
retention O +
of O +
the O +
skill O +
over O +
a O +
30-min O +
delay O +
interval O -
, O +
and O +
generalization O +
of O +
the O +
skill O +
to O +
a O +
new O +
figure O +
or O +
to O +
the O +
opposite O +
direction O +
of O +
tracing O -
. O +

The O +
AD B-Disease +
patients O +
who O +
were O +
unable O +
to O +
initially O +
perform O +
the O +
mirror O +
tracing O +
task O +
were O +
significantly O +
worse O +
than O +
those O +
who O +
could O +
perform O +
the O +
task O +
on O +
several O +
neuropsychological O +
measures O +
sensitive O +
to O +
deficits O +
in O +
problem O +
solving O +
and O +
executive O +
functions O -
, O +
but O +
not O +
on O +
tests O +
of O +
global O +
cognitive O +
decline O -
, O +
memory O -
, O +
language O -
, O +
or O +
visuoperceptual O +
functioning O -
. O +

These O +
results O +
indicate O +
that O +
acquisition O +
and O +
retention O +
of O +
a O +
complex O +
visuomotor O +
skill O +
can O +
proceed O +
normally O +
in O +
the O +
early O +
stages O +
of O +
AD B-Disease +
in O +
those O +
individuals O +
who O +
can O +
initially O +
perform O +
the O +
basic O +
task O -
, O +
and O +
that O +
inability O +
to O +
perform O +
the O +
basic O +
task O +
may O +
be O +
related O +
to O +
the O +
frontal B-Disease +
lobe I-Disease +
dysfunction I-Disease +
that O +
is O +
often O +
prominent O +
in O +
the O +
disorder O -
. O +

Thus O -
, O +
miR-206 O +
slows O +
ALS B-Disease +
progression O +
by O +
sensing B-Disease +
motor I-Disease +
neuron I-Disease +
injury I-Disease +
and O +
promoting O +
the O +
compensatory O +
regeneration O +
of O +
neuromuscular O +
synapses O -
. O +

Here O -
, O +
we O +
show O +
that O +
a O +
key O +
regulator O +
of O +
this O +
signaling O +
is O +
miR-206 O -
, O +
a O +
skeletal O +
muscle O -
- O -
specific O +
microRNA O +
that O +
is O +
dramatically O +
induced O +
in O +
a O +
mouse O +
model O +
of O +
ALS B-Disease -
. O +

Mice O +
that O +
are O +
genetically O +
deficient O +
in O +
miR-206 O +
form O +
normal O +
neuromuscular O +
synapses O +
during O +
development O -
, O +
but O +
deficiency O +
of O +
miR-206 O +
in O +
the O +
ALS B-Disease +
mouse O +
model O +
accelerates O +
disease O +
progression O -
. O +

miR-206 O +
is O +
required O +
for O +
efficient O +
regeneration O +
of O +
neuromuscular O +
synapses O +
after O +
acute B-Disease +
nerve I-Disease +
injury I-Disease -
, O +
which O +
probably O +
accounts O +
for O +
its O +
salutary O +
effects O +
in O +
ALS B-Disease -
. O +

miR-206 O +
mediates O +
these O +
effects O +
at O +
least O +
in O +
part O +
through O +
histone O +
deacetylase O +
4 O +
and O +
fibroblast O +
growth O +
factor O +
signaling O +
pathways O -
. O +

MicroRNA-206 O +
delays O +
ALS B-Disease +
progression O +
and O +
promotes O +
regeneration O +
of O +
neuromuscular O +
synapses O +
in O +
mice O -
. O +

Amyotrophic B-Disease +
lateral I-Disease +
sclerosis I-Disease +
( O -
ALS B-Disease -
) O +
is O +
a O +
neurodegenerative B-Disease +
disease I-Disease +
characterized O +
by O +
loss O +
of O +
motor O +
neurons O -
, O +
denervation O +
of O +
target O +
muscles O -
, O +
muscle B-Disease +
atrophy I-Disease -
, O +
and O +
paralysis B-Disease -
. O +

Understanding O +
ALS B-Disease +
pathogenesis O +
may O +
require O +
a O +
fuller O +
understanding O +
of O +
the O +
bidirectional O +
signaling O +
between O +
motor O +
neurons O +
and O +
skeletal O +
muscle O +
fibers O +
at O +
neuromuscular O +
synapses O -
. O +

[ O -
A O +
study O +
on O +
miRNA O +
alternation O +
after O +
H2O2-induced O +
PC12 O +
cell O +
apoptosis O +
using O +
microarray O +
technique O -
] O -
. O +

METHODS O -
: O +
PC12 O +
cells O +
were O +
treated O +
with O +
different O +
concentrations O +
of O +
H2O2 O +
for O +
12 O +
hours O -
, O +
and O +
then O +
the O +
cell O +
viabilities O +
were O +
evaluated O +
by O +
MTT O +
assay O +
and O +
cell O +
apoptosis O +
rates O +
were O +
assessed O +
by O +
flow O +
cytometry O +
( O -
FCM O -
) O -
. O +

OBJECTIVE O -
: O +
To O +
screen O +
the O +
differentially O +
expressed O +
microRNAs O -
( O -
miRNA O -
) O +
between O +
H2O2-induced O +
PC12 O +
cell O +
apoptosis O +
and O +
normal O +
PC12 O +
cells O +
with O +
microarray O +
chips O -
. O +

Of O +
the O +
46 O +
miRNAs O +
in O +
the O +
H2O2 O +
treated O +
groups O -
, O +
39 O +
were O +
similar O +
to O +
that O +
of O +
the O +
control O +
group O +
and O +
6 O +
were O +
significantly O +
down O -
- O -
regulated O -
. O +

CONCLUSION O -
: O +
Our O +
preliminary O +
data O +
may O +
provide O +
a O +
new O +
potential O +
foundation O +
for O +
further O +
study O +
of O +
pathogenesis O +
and O +
its O +
treatment O +
of O +
nerve O +
cell O +
apoptosis O +
caused O +
by O +
cerebral B-Disease +
ischemia I-Disease +
reperfusion I-Disease -
. O +

The O +
apoptosis O +
rates O +
for O +
them O +
were O +
2.6 O -
% O -
, O +
5.2 O -
% O -
, O +
7.2 O -
% O -
, O +
10.4 O -
% O -
, O +
16.6 O -
% O -
, O +
and O +
72.2 O -
% O +
accordingly O -
. O +

Expression O +
of O +
68 O +
miRNAs O +
and O +
46 O +
miRNAs O +
were O +
detected O +
in O +
both O +
control O +
group O +
and O +
the O +
H2O2 O +
treated O +
groups O -
. O +

miRNAs O +
were O +
isolated O +
from O +
control O +
( O -
0 O +
nmol O -
/ O -
L O +
H2O2 O -
) O +
and O +
H2O2 O +
treated O +
( O -
at O +
concentrations O +
of O +
50 O -
, O +
100 O -
, O +
200 O -
, O +
and O +
400 O +
nmol O -
/ O -
L O +
H2O2 O -
, O +
respectively O -
) O +
groups O +
of O +
the O +
PC12 O +
cells O -
, O +
respectively O -
, O +
and O +
were O +
then O +
detected O +
and O +
analyzed O +
by O +
microarray O +
chips O -
. O +

RESULTS O -
: O +
The O +
P12 O +
cell O +
viabilities O +
in O +
control O +
and O +
H2O2 O +
treated O +
group O +
were O +
( O -
92 O +
+ O -
/- O +
9.8 O -
) O -
% O -
, O +
( O -
90 O +
+ O -
/- O +
14.70 O -
) O -
% O -
, O +
( O -
80 O +
+ O -
/- O +
13.85 O -
) O -
% O -
, O +
( O -
54 O +
+ O -
/- O +
12.23 O -
) O -
% O -
, O +
and O +
( O -
22 O +
+ O -
/- O +
7.35 O -
) O -
% O -
, O +
respectively O -
. O +

In O +
particular O -
, O +
SNP O +
rs12720208 O +
in O +
the O +
3 O -
' O +
untranslated O +
region O +
( O -
3 O -
' O +
UTR O -
) O +
was O +
linked O +
to O +
PD B-Disease -
- O -
risk O +
through O +
a O +
mechanism O +
that O +
would O +
implicate O +
a O +
differential O +
binding O +
to O +
microRNA-433 O +
( O -
miR-433 O -
) O -
. O +

The O +
reduction O +
of O +
the O +
affinity O +
of O +
miR-433 O +
to O +
the O +
3 O -
' O +
UTR O +
would O +
result O +
in O +
increased O +
FGF20 O +
expression O +
and O +
upregulation O +
of O +
alpha O -
- O -
synuclein O -
, O +
which O +
could O +
in O +
turn O +
promote O +
dopaminergic O +
neurons O +
degeneration O -
. O +

FGF20 O +
rs12720208 O +
SNP O +
and O +
microRNA-433 O +
variation O -
: O +
no O +
association O +
with O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
in O +
Spanish O +
patients O -
. O +

DNA O +
variation O +
at O +
the O +
FGF20 O +
gene O +
has O +
been O +
associated O +
with O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
( O -
PD B-Disease -
) O -
. O +

In O +
conclusion O -
, O +
our O +
work O +
did O +
not O +
confirm O +
the O +
association O +
between O +
rs12720208 O +
and O +
PD B-Disease -
, O +
or O +
an O +
effect O +
of O +
miR-433 O +
variants O +
on O +
this O +
disease O -
. O +

None O +
of O +
the O +
patients O +
had O +
miR-433 O +
variants O -
. O +

We O +
did O +
not O +
find O +
significant O +
differences O +
in O +
allele O +
and O +
genotype O +
frequencies O +
between O +
patients O +
and O +
controls O -
. O +

We O +
genotyped O +
the O +
rs12720208 O +
SNP O +
in O +
a O +
total O +
of O +
512 O +
PD B-Disease +
patients O +
and O +
258 O +
healthy O +
controls O +
from O +
Spain O -
, O +
and O +
searched O +
for O +
miR-433 O +
variants O +
in O +
the O +
patients O -
. O +

The O +
results O +
suggest O +
( O -
a O -
) O +
that O +
unless O +
specifically O +
stabilized O -
, O +
certain O +
brain O -
- O -
enriched O +
miRNAs O +
represent O +
a O +
rapidly O +
executed O +
signaling O +
system O +
employing O +
highly O +
transient O +
effectors O +
of O +
CNS O +
gene O +
expression O -
, O +
and O +
( O -
b O -
) O +
that O +
in O +
AD B-Disease +
temporal O +
lobe O +
neocortex O +
specific O +
brain O +
miRNAs O +
are O +
significantly O +
up O -
- O -
regulated O +
in O +
abundance O +
and O +
strongly O +
correlate O +
with O +
the O +
presence O +
of O +
AD B-Disease -
- O -
type O +
neuropatholgical O +
change O -
. O +

In O +
short O +
PMI O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease +
( O -
AD B-Disease -
) O -
-affected O +
temporal O +
lobe O +
neocortex O -
, O +
miRNA-9 O -
, O +
miRNA-125b O +
and O +
miRNA-146a O +
were O +
found O +
to O +
be O +
significantly O +
up O -
- O -
regulated O -
, O +
an O +
effect O +
that O +
was O +
not O +
seen O +
in O +
several O +
related O +
neurological B-Disease +
disorders I-Disease -
. O +

In O +
these O +
studies O -
, O +
miRNA O +
array O +
and O +
Northern O +
blot O +
based O +
tracking O +
of O +
specific O +
miRNA O +
abundances O +
and O +
decay O +
kinetics O +
in O +
human O +
neural O +
( O -
HN O -
) O +
cells O +
in O +
primary O +
culture O +
and O +
in O +
short O +
post O -
- O -
mortem O +
interval O +
( O -
PMI O -
, O +
approximately O +
1h O -
) O +
human O +
brain O +
tissues O +
showed O +
a O +
limited O +
stability O +
and O +
relatively O +
short O +
half O -
- O -
life O +
( O +
approximately O +
1 O -
- O -
3.5h O -
) O +
for O +
specific O +
brain O -
- O -
enriched O +
miRNAs O -
. O +

Micro O -
- O -
RNA O +
( O -
miRNA O -
) O +
mediated O +
regulation O +
of O +
messenger O +
RNA O +
( O -
mRNA O -
) O +
complexity O +
in O +
the O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
is O +
emerging O +
as O +
a O +
critical O +
factor O +
in O +
the O +
control O +
of O +
CNS O -
- O -
specific O +
gene O +
expression O +
during O +
development O -
, O +
plasticity O -
, O +
aging O +
and O +
disease O -
. O +

Micro O -
- O -
RNA O +
abundance O +
and O +
stability O +
in O +
human O +
brain O -
: O +
specific O +
alterations O +
in O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease +
temporal O +
lobe O +
neocortex O -
. O +

Keystone O +
symposium O -
, O +
Neurodegenerative B-Disease +
Diseases I-Disease -
: O +
New O +
Molecular O +
Mechanisms O +
17 O -
- O -
22 O +
February O +
2009 O -
. O +

Glioma B-Disease +
angiogenesis O -
: O +
Towards O +
novel O +
RNA O +
therapeutics O -
. O +

Brain B-Disease +
tumors I-Disease +
exhibit O +
marked O +
and O +
aberrant O +
blood O +
vessel O +
formation O +
indicating O +
angiogenic O +
endothelial O +
cells O +
as O +
a O +
potential O +
target O +
for O +
brain B-Disease +
tumor I-Disease +
treatment O -
. O +

The O +
brain B-Disease +
tumor I-Disease +
blood O +
vessels O +
are O +
used O +
for O +
nutrient O +
delivery O -
, O +
and O +
possibly O +
for O +
cancer B-Disease +
cell O +
migration O -
. O +

The O +
process O +
of O +
angiogenesis O +
is O +
complex O +
and O +
involves O +
multiple O +
players O -
. O +

The O +
current O +
angiogenesis O +
inhibitors O +
used O +
in O +
clinical O +
trials O +
mostly O +
target O +
single O +
angiogenic O +
proteins O +
and O +
so O +
far O +
show O +
limited O +
effects O +
on O +
tumor B-Disease +
growth O -
. O +

Besides O +
the O +
conventional O +
angiogenesis O +
inhibitors O -
, O +
RNA O -
- O -
based O +
inhibitors O +
such O +
as O +
small O -
- O -
interfering O +
RNAs O +
( O -
siRNAs O -
) O +
are O +
being O +
analyzed O +
for O +
their O +
capacity O +
to O +
silence O +
the O +
message O +
of O +
proteins O +
involved O +
in O +
neovascularization O -
. O +

More O +
recently O -
, O +
a O +
new O +
family O +
of O +
non O -
- O -
coding O +
RNAs O -
, O +
named O +
angiomirs O +
[ O -
microRNAs O +
( O -
miRNAs O -
) O +
involved O +
in O +
angiogenesis O -
] O +
has O +
emerged O -
. O +

These O +
small O +
RNAs O +
have O +
the O +
advantage O +
over O +
siRNAs O +
in O +
that O +
they O +
have O +
the O +
potential O +
of O +
silencing O +
multiple O +
messages O +
at O +
the O +
same O +
time O +
and O +
therefore O +
they O +
might O +
become O +
therapeutically O +
relevant O +
in O +
a O +
" O -
one O -
- O -
hit O +
multiple O -
- O -
target O -
" O +
context O +
against O +
brain B-Disease +
tumor I-Disease +
angiogenesis O -
. O +

In O +
this O +
review O +
we O +
will O +
discuss O +
the O +
emerging O +
technologies O +
in O +
anti O -
- O -
angiogenesis O +
emphasizing O +
on O +
RNA O -
- O -
based O +
therapeutics O -
. O +

Diseases O +
potentially O +
mediated O +
by O +
alterations O +
in O +
RNA O +
processes O +
include O +
tauopathies B-Disease -
, O +
myotonic B-Disease +
dystrophy I-Disease -
, O +
Alzheimer B-Disease +
disease I-Disease -
, O +
brain B-Disease +
cancer I-Disease -
, O +
and O +
many O +
others O -
. O +

Some O +
noncoding O +
RNAs O +
have O +
been O +
shown O +
to O +
be O +
involved O +
in O +
human B-Disease +
brain I-Disease +
diseases I-Disease -
. O +

Furthermore O -
, O +
there O +
is O +
poor O +
correlation O +
between O +
mRNA O +
levels O +
and O +
protein O +
levels O +
in O +
mammalian O +
cells O -
, O +
due O +
partly O +
to O +
complicated O +
post O -
- O -
transcriptional O +
regulation O +
by O +
hitherto O +
unknown O +
noncoding O +
RNAs O -
. O +

For O +
example O -
, O +
neurologic B-Disease +
illnesses I-Disease +
may O +
arise O +
because O +
of O +
perturbations O +
in O +
distinct O +
but O +
interrelated O +
tiers O +
of O +
RNA O -
- O -
based O +
genetic O +
regulation O -
: O +
pre O -
- O -
mRNA O +
splicing O -
; O +
nonsplicing O +
RNA O +
modifications O -
; O +
and O +
mRNA O +
translational O +
regulation O -
. O +

A O +
variety O +
of O +
unforeseen O +
complexities O +
have O +
been O +
identified O -
, O +
many O +
with O +
relevance O +
to O +
human B-Disease +
brain I-Disease +
disease I-Disease -
. O +

RNA O +
research O +
has O +
made O +
great O +
progress O +
in O +
recent O +
years O -
. O +

RNA O +
in O +
brain B-Disease +
disease I-Disease -
: O +
no O +
longer O +
just O +
" O -
the O +
messenger O +
in O +
the O +
middle O -
" O -
. O +

Here O +
we O +
present O +
an O +
overview O +
of O +
new O +
research O +
highlighting O +
functions O +
for O +
RNA O +
that O +
far O +
surpass O +
the O +
" O -
messenger O +
in O +
the O +
middle O -
" O +
role O +
and O +
that O +
identify O +
RNA O +
molecules O +
as O +
important O +
agents O +
in O +
the O +
human O +
brain O +
in O +
health O +
and O +
in O +
disease O +
states O -
. O +

RNA O +
editing O +
by O +
adenosine O +
deamination O +
is O +
a O +
posttranscriptional O +
mechanism O +
for O +
the O +
regulation O +
of O +
gene O +
expression O +
and O +
is O +
particularly O +
widespread O +
in O +
mammals O -
. O +

Gene O +
regulation O +
through O +
RNA O +
editing O -
. O +

Here O -
, O +
I O +
am O +
reviewing O +
main O +
features O +
of O +
this O +
epigenetic O +
phenomenon O -
, O +
its O +
relevance O +
for O +
health O +
and O +
disease O -
, O +
as O +
well O +
as O +
potential O +
prospects O +
for O +
using O +
RNA O +
editing O +
as O +
a O +
therapeutic O +
tool O -
. O +

Widespread O +
A O -
- O -
to O -
- O -
I O +
modification O +
of O +
repeat O +
sequences O +
in O +
the O +
human O +
transcriptome O +
suggests O +
additional O +
roles O +
for O +
RNA O +
editing O +
and O +
links O +
it O +
to O +
other O +
processes O +
of O +
gene O +
regulation O -
, O +
such O +
as O +
RNA O +
splicing O +
as O +
well O +
as O +
siRNA O +
mediated O +
gene O +
silencing O +
and O +
miRNA O +
function O -
. O +

The O +
deficiency O +
or O +
misregulation O +
of O +
editing O +
has O +
been O +
implicated O +
in O +
the O +
etiology O +
of O +
neurological B-Disease +
diseases I-Disease -
, O +
such O +
as O +
epilepsy B-Disease -
, O +
amyotrophic B-Disease +
lateral I-Disease +
sclerosis I-Disease +
( O -
ALS B-Disease -
) O -
, O +
depression B-Disease +
and O +
tumor B-Disease +
progression O -
. O +

Also O -
, O +
it O +
regulates O +
important O +
functional O +
properties O +
of O +
neurotransmitter O +
receptor O +
genes O +
in O +
the O +
central O +
nervous O +
system O +
by O +
changing O +
single O +
codons O +
in O +
pre O -
- O -
mRNA O -
. O +

A O -
- O -
to O -
- O -
I O +
RNA O +
editing O +
generates O +
transcriptome O +
and O +
proteome O +
diversity O +
allowing O +
organisms O +
to O +
produce O +
many O +
more O +
gene O +
products O +
and O +
functions O +
than O +
predicted O +
based O +
on O +
the O +
number O +
of O +
genes O +
within O +
their O +
genome O -
. O +

Gliomas B-Disease +
display O +
a O +
microRNA O +
expression O +
profile O +
reminiscent O +
of O +
neural O +
precursor O +
cells O -
. O +

Gliomas B-Disease +
express O +
many O +
genes O +
that O +
play O +
a O +
role O +
in O +
neural O +
precursor O +
cells O +
( O -
NPCs O -
) O -
, O +
but O +
no O +
direct O +
comparison O +
between O +
glioma B-Disease +
and O +
stem O +
cell O +
( O -
SC O -
) O +
gene O +
expression O +
profiles O +
has O +
been O +
performed O -
. O +

To O +
investigate O +
the O +
similarities O +
and O +
differences O +
between O +
gliomas B-Disease +
and O +
SCs O -
, O +
we O +
compared O +
the O +
microRNA O +
( O -
miRNA O -
) O +
expression O +
signatures O +
of O +
glial B-Disease +
tumors I-Disease -
, O +
embryonic O +
SCs O +
( O -
ESCs O -
) O -
, O +
NPCs O -
, O +
and O +
normal O +
adult O +
brains O +
from O +
both O +
human O +
and O +
mouse O +
tissues O -
. O +

We O +
demonstrated O +
that O +
both O +
human B-Disease +
gliomas I-Disease +
( O -
regardless O +
of O +
their O +
grade O -
) O +
and O +
methylcholanthrene O -
- O -
induced O +
mouse B-Disease +
glioma I-Disease +
shared O +
an O +
miRNA O +
expression O +
profile O +
that O +
is O +
reminiscent O +
of O +
NPCs O -
. O +

About O +
half O +
of O +
the O +
miRNAs O +
expressed O +
in O +
the O +
shared O +
profile O +
clustered O +
in O +
seven O +
genomic O +
regions O +
susceptible O +
to O +
genetic O -
/ O -
epigenetic O +
alterations O +
in O +
various O +
cancers B-Disease -
. O +

These O +
clusters O +
comprised O +
the O +
miR17 O +
family O -
, O +
mir183 O -
- O -
182 O -
, O +
and O +
the O +
SC O -
- O -
specific O +
clusters O +
mir367 O -
- O -
302 O +
and O +
mir371 O -
- O -
373 O -
, O +
which O +
are O +
upregulated O +
in O +
gliomas B-Disease -
, O +
ESCs O -
, O +
and O +
NPCs O -
. O +

The O +
bipartite O +
cluster O +
of O +
7 O +
+ O +
46 O +
miRNAs O +
on O +
chromosome O +
14q32.31 O -
, O +

which O +
might O +
represent O +
the O +
largest O +
tumor O +
suppressor O +
miRNA O +
cluster O -
, O +
was O +
downregulated O +
in O +
the O +
shared O +
expression O +
profile O -
. O +

This O +
study O +
provides O +
the O +
first O +
evidence O +
for O +
association O +
between O +
these O +
clusters O +
and O +
gliomas B-Disease -
. O +

Despite O +
the O +
broad O +
similarity O +
in O +
the O +
miRNA O +
expression O +
profiles O -
, O +
15 O +
miRNAs O +
showed O +
disparate O +
expression O +
between O +
SC O +
and O +
gliomas B-Disease -
. O +

Ten O +
miRNAs O +
belong O +
to O +
the O +
2 O +
SC O -
- O -
specific O +
clusters O +
and O +
the O +
remaining O +
( O -
mir135b O -
, O +
mir141 O -
, O +
mir205 O -
, O +
mir200C O -
, O +
and O +
mir301a O -
) O +
have O +
been O +
previously O +
shown O +
to O +
associate O +
with O +
malignancies O -
. O +

Our O +
finding O +
showed O +
that O +
all O +
gliomas B-Disease +
displayed O +
NPC O -
- O -
like O +
miRNA O +
signatures O -
, O +
which O +
may O +
have O +
implications O +
for O +
studies O +
of O +
glioma B-Disease +
origins O -
. O +

Furthermore O -
, O +
careful O +
study O +
of O +
the O +
15 O +
miRNAs O +
that O +
differ O +
in O +
expression O +
between O +
SCs O +
and O +
gliomas B-Disease -
, O +
particularly O +
those O +
5 O +
that O +
are O +
not O +
SC O -
- O -
specific O -
, O +
may O +
enhance O +
our O +
understanding O +
of O +
gliomagenesis O -
. O +

New O +
insights O +
into O +
the O +
roles O +
of O +
microRNAs O +
in O +
drug B-Disease +
addiction I-Disease +
and O +
neuroplasticity O -
. O +

In O +
this O +
review O -
, O +
the O +
aim O +
is O +
to O +
provide O +
an O +
overview O +
of O +
the O +
emerging O +
role O +
of O +
miRNAs O +
in O +
addiction O -
. O +

miRNAs O +
are O +
small O +
non O -
- O -
coding O +
RNAs O -
, O +
particularly O +
abundant O +
in O +
the O +
nervous O +
system O -
, O +
that O +
play O +
key O +
roles O +
as O +
regulatory O +
molecules O +
in O +
processes O +
such O +
as O +
neurogenesis O -
, O +
synapse O +
development O +
and O +
plasticity O +
in O +
the O +
brain O -
. O +

They O +
also O +
act O +
as O +
key O +
spatiotemporal O +
regulators O +
during O +
dendritic O +
morphogenesis O -
, O +
controlling O +
the O +
expression O +
of O +
hundreds O +
of O +
genes O +
involved O +
in O +
neuroplasticity O +
and O +
in O +
the O +
function O +
of O +
synapses O -
. O +

Recent O +
studies O +
have O +
identified O +
changes O +
of O +
several O +
specific O +
miRNA O +
expression O +
profiles O +
and O +
polymorphisms O +
affecting O +
the O +
interactions O +
between O +
miRNAs O +
and O +
their O +
targets O +
in O +
various O +
brain B-Disease +
disorders I-Disease -
, O +
including O +
addiction O -
: O +
miR-16 O +
causes O +
adaptive O +
changes O +
in O +
production O +
of O +
the O +
serotonin O +
transporter O -
; O +
miR-133b O +
is O +
specifically O +
expressed O +
in O +
midbrain O +
dopaminergic O +
neurons O -
, O +
and O +
regulates O +
the O +
production O +
of O +
tyrosine O +
hydroxylase O +
and O +
the O +
dopamine O +
transporter O -
; O +
miR-212 O +
affects O +
production O +
of O +
striatal O +
brain O -
- O -
derived O +
neurotrophic O +
factor O +
and O +
synaptic O +
plasticity O +
upon O +
cocaine O -
. O +

Clearly O -
, O +
specific O +
miRNAs O +
have O +
emerged O +
as O +
key O +
regulators O +
leading O +
to O +
addiction O -
, O +
and O +
could O +
serve O +
as O +
valuable O +
targets O +
for O +
more O +
efficient O +
therapies O -
. O +

ABSTRACT O +
: O +
Drug B-Disease +
addiction I-Disease +
is O +
a O +
major O +
public O +
health O +
issue O -
. O +

It O +
is O +
typically O +
a O +
multigenetic O +
brain B-Disease +
disorder I-Disease -
, O +
implying O +
combined O +
changes O +
of O +
expression O +
of O +
several O +
hundred O +
genes O -
. O +

Psychostimulants O +
( O -
such O +
as O +
cocaine O -
, O +
heroin O +
and O +
amphetamines O -
) O +
induce O +
strong O +
and O +
persistent O +
neuroadaptive O +
changes O +
through O +
a O +
surfeit O +
of O +
gene O +
regulatory O +
mechanisms O +
leading O +
to O +
addiction O -
. O +

Activity O -
- O -
dependent O +
synaptic O +
plasticity O +
of O +
the O +
mesolimbic O +
dopaminergic O +
system O -
, O +
known O +
as O +
the O +
' O -
reward O +
pathway O -
' O -
, O +
plays O +
a O +
crucial O +
role O +
in O +
the O +
development O +
of O +
drug B-Disease +
dependence I-Disease -
. O +

